Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T36098
|
||||
Former ID |
TTDS00372
|
||||
Target Name |
Farnesyl pyrophosphatesynthetase
|
||||
Synonyms |
FPP synthase; FPP synthetase; FPPS; FPS; Farnesyl diphosphate synthase; Farnesyl diphosphate synthetase; Farnesyl pyrophosphatesynthase
|
||||
Target Type |
Successful
|
||||
Disease | Bone disease [ICD10: M00-M99] | ||||
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | |||||
Hypercalcemia [ICD9: 275.42; ICD10: E83.5] | |||||
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890] | |||||
Paget's disease [ICD9: 731; ICD10: M88] | |||||
Function |
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
|
||||
BioChemical Class |
Alkyl aryl transferase
|
||||
Target Validation |
T36098
|
||||
EC Number |
EC 2.5.1.1
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Incadronate | Drug Info | Approved | Hypercalcemia | [551871] |
Minodronate | Drug Info | Approved | Osteoporosis | [546292], [551871] | |
NERIDRONIC ACID | Drug Info | Approved | Bone disease | [551871] | |
Pamidronate | Drug Info | Approved | Hypercalcemia | [536957], [542277] | |
Risedronate | Drug Info | Approved | Paget's disease | [537304], [540158] | |
Inhibitor | (1-hydroxy-1-phosphono-heptyl)-phosphonic acid | Drug Info | [529229] | ||
(biphenyl-3-ylamino)methylenediphosphonic acid | Drug Info | [529690] | |||
1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid | Drug Info | [529229] | |||
1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid | Drug Info | [529229] | |||
1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid | Drug Info | [529229] | |||
1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid | Drug Info | [529229] | |||
1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid | Drug Info | [529229] | |||
1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid | Drug Info | [529229] | |||
1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid | Drug Info | [529229] | |||
1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid | Drug Info | [529229] | |||
Bisphosphonates | Drug Info | [535202] | |||
compound 2 | Drug Info | [529334] | |||
compound 31 | Drug Info | [529121] | |||
compound 5e | Drug Info | [529126] | |||
Dimethylallyl Diphosphate | Drug Info | [551374] | |||
diphosphoric acid | Drug Info | [529362] | |||
Geranyl Diphosphate | Drug Info | [551393] | |||
GERANYLGERANYL DIPHOSPHATE | Drug Info | [551374] | |||
Homorisedronate | Drug Info | [535202] | |||
Incadronate | Drug Info | [535102] | |||
ISOPENTENYL PYROPHOSPHATE | Drug Info | [551374] | |||
Isopentyl Pyrophosphate | Drug Info | [551393] | |||
Minodronate | Drug Info | [535102] | |||
minodronic acid | Drug Info | [530855] | |||
NE-10575 | Drug Info | [529362] | |||
NE10790 | Drug Info | [529362] | |||
NE11808 | Drug Info | [529362] | |||
NE21650 | Drug Info | [535340] | |||
NE58018 | Drug Info | [529362] | |||
NE58027 | Drug Info | [529362] | |||
NE58043 | Drug Info | [529362] | |||
NE58062 | Drug Info | [529362] | |||
NE97220 | Drug Info | [529362] | |||
NERIDRONIC ACID | Drug Info | [529362] | |||
Pamidronate | Drug Info | [536847] | |||
Piridronic acid | Drug Info | [529362] | |||
RIS | Drug Info | [535372] | |||
Risedronate | Drug Info | [535496] | |||
[2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
[2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
[2-(Imidazol-1-yl)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
[2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
[2-(Purin-9-yl)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
[2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid | Drug Info | [529758] | |||
Pathways | |||||
KEGG Pathway | Terpenoid backbone biosynthesis | ||||
Metabolic pathways | |||||
Biosynthesis of antibiotics | |||||
Influenza A | |||||
HTLV-I infection | |||||
PathWhiz Pathway | Steroid Biosynthesis | ||||
Reactome | Cholesterol biosynthesis | ||||
Activation of gene expression by SREBF (SREBP) | |||||
WikiPathways | Activation of Gene Expression by SREBP (SREBF) | ||||
SREBP signalling | |||||
Cholesterol Biosynthesis | |||||
References | |||||
Ref 536957 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. | ||||
Ref 540158 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3176). | ||||
Ref 542277 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7259). | ||||
Ref 529121 | Activity of sulfonium bisphosphonates on tumor cell lines. J Med Chem. 2007 Nov 29;50(24):6067-79. Epub 2007 Oct 27. | ||||
Ref 529126 | Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007 Nov 29;50(24):5967-75. Epub 2007 Nov 2. | ||||
Ref 529229 | Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. Epub 2007 Dec 10.Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. | ||||
Ref 529334 | Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett.2008 Mar 15;18(6):1840-4. | ||||
Ref 529362 | J Med Chem. 2008 Apr 10;51(7):2187-95. Epub 2008 Mar 8.Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. | ||||
Ref 529690 | Bioorg Med Chem. 2008 Oct 1;16(19):8959-67. Epub 2008 Aug 27.Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation. | ||||
Ref 529758 | J Med Chem. 2008 Nov 13;51(21):6800-7. Epub 2008 Oct 21.Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. | ||||
Ref 530855 | Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64. | ||||
Ref 535102 | Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. | ||||
Ref 535202 | Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 2001 Sep 7;276(36):33930-7. Epub 2001 Jul 2. | ||||
Ref 535340 | Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun. 2002 Jan 18;290(2):869-73. | ||||
Ref 535372 | In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother. 2002 Mar;46(3):929-31. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.